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ABSTRACT
There is a need to improve the rational use of antibiotics across continents including Africa. This has
resulted in initiatives in Botswana including treatment guidelines and the instigation of Antibiotic
Stewardship Programs (ASPs). The next steps involve a greater understanding of current antibiotic
utilization and resistance patterns (AMR). This resulted in a 2-day meeting involving key stakeholders
principally from Botswana to discuss key issues including AMR rates as well as ASPs in both the public
and private sectors. Following this, the findings will be used to plan future studies across Africa
including point prevalence studies. The findings will be presented in July 2016 at the next Medicines
Utilization Research in Africa meeting will ideally serve as a basis for planning future pertinent
interventional studies to enhance the rational use of antibiotics in Botswana and wider.
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Meeting
Greater accessibility to antibiotics has contributed to their irra-
tional and excessive use [1–3], leading to increasing antimicro-
bial resistance (AMR), a decline in their effectiveness, and a strain
on health-care systems [4]. Irrational use is not helped by self-
purchasing of antibiotics, which is common in many countries
including African countries across awide range of infections [5,6].
It is estimated that AMR infections currently cause
approximately 50,000 deaths a year in Europe and the US
alone, increasing to several hundred thousand when other
countries are included [7,8]. The continual rise in AMR could
result in infections that are resistant to antibiotics, becom-
ing a leading cause of death by 2050, with a clear link
between overuse of antibiotics and AMR. This will signifi-
cantly impact on the wealth of nations, potentially costing
up to US$100 trillion/year by 2050 [1,7,9–11].
These concerns have resulted in strategies across coun-
tries to reduce inappropriate use, including the instigation
of multifaceted approaches in the community as well as
antibiotic stewardship programs (ASPs) especially in hospi-
tals, where antibiotics can account for up to 35% of medi-
cine expenditure, with the World Health Organization
(WHO) playing a leading role [3,5,8,11–14]. The prevalence
of HIV-related opportunistic infections including TB, malaria,
and sexually transmitted infections have also increased the
demand and cost of antibiotics prescribed within hospitals.
There have been combined activities in Botswana to improve
the use of antibiotics, including the development of antibiotic
guidelines and other measures; however, research has shown
that guidelines are not always followed and there are concerns
with the extent of empiric use and limited use of sensitivity
analyses in some hospitals [5,15]. These concerns resulted in
initiatives in both public and private sectors in Botswana to docu-
ment current activities, including resistance patterns, as well as
plan future research activities in both ambulatory and hospital
care. This was the basis of this 2-day meeting, which also included
representatives from the WHO as well as other African countries.
The meeting was opened by the University of Botswana’s
Dean of the Faculty of Medicine, followed by Brian Godman
(Karolinska University Hospital, Sweden) giving a brief intro-
duction to drug utilization research, including the Anatomical
Therapeutic Chemical/ Defined Daily Dose (ATC/DDD) classifi-
cation as a standard means for collecting and comparing drug
utilization patterns within and between countries [16]. In addi-
tion, Godman introduced the Medicines Utilization Research in
Africa (MURIA) group. MURIA activities to-date include two
meetings in 2015 to develop and progress drug utilization
capabilities [5,17]. National and cross-national studies allied
to health policies pave the way to plan future measures
since without such studies planning is difficult. This strategy
has worked well across Europe and beyond involving multiple
classes of medicines [13,18–20].
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Abayneh Desta (WHO Regional Office for Africa, Republic of
Congo) discussed concerns and issues with antibiotic prescrib-
ing in Africa. These included weak laboratory capacity, poor
compliance to prescribed medicines—not helped by the high
cost of some treatments, considerable self-medication, and
poor health information systems. These factors influence the
development of AMR, jeopardizing the health of individuals
and society. The WHO has undertaken a number of activities
to address this, including guidelines for establishing Drugs
and Therapeutic Committees (DTCs) as well as strategies, poli-
cies, and other documents to reduce AMR [8,11,21]. Ways
forward include strengthening the knowledge and evidence
base, and optimizing the use of antibiotics. The latter includes
implementing targeted strategies to reduce inappropriate use
of antibiotics informed by AMR surveillance data. These
include well-functioning DTCs and ASPs as well as evaluating
current utilization patterns. Arno Muller emphasized the ATC/
DDD methodology for comparing utilization across countries,
and discussed projects comparing antimicrobial consumption
in both ambulatory care and hospitals [22]. Muller also dis-
cussed current Point Prevalence Studies (PPS) as a basis for
potential studies in Botswana and other African countries [23].
Advantages of PPS include greater knowledge of current anti-
biotic use in individual hospitals, which can subsequently
provide a baseline to assess different targeted interventions,
which could be part of ASPs. PPS also enable comparisons
nationally and cross-nationally if standardized protocols are
used to improve future antibiotic use. Challenges include
resource requirements and the inherent heterogeneity
between hospitals.
Celda Tiroyakosi (Ministry of Health, Botswana) discussed
ongoing activities in Botswana to enhance appropriate anti-
biotic use through the National Standing Committee on
Drugs, hospital DTCs, and the revision and implementation
of the Botswana Antimicrobial Therapy Guidelines in 2012.
The second edition of the guideline was divided into 12
chapters and 5 appendices including suggested antibiotic
regimes for a range of infections to guide prescribers on the
most cost-effective option. It also suggested second-line
options such as Clarithromycin for H. pylori as well as com-
ments on their side effects, resulting in a promotion of con-
sistency in the treatment of infections. The guideline also
places restrictions on the use of certain antibiotics to reduce
inappropriate use, for example, amikacin and fluoroquinolones
for multi-drug resistant-TB; however, there is concern that the
guidelines are not regularly used, which needs to be
addressed.
Bene Paramadhas (University of South Africa, South Africa)
discussed microbial prevalence and antibiotic sensitivities
from 2012 to 2015 in Nyangabgwe Hospital. The most com-
mon isolates included E. coli, Staphylococcus aureus, and
Klebsiella pneumoniae. Prevalence rates were greater in adults
and differences were observed in males and females.
Resistance of S. aureus and Streptococci spp to penicillin-G
was 99% and 70%, respectively; E. coli to ampicillin, 77%;
K. pneumonia and E. coli to cefotaxime 62% and 47%, respec-
tively; K. pneumonia and E. coli to amoxicillin plus clavulanic
acid 52% and 24%, respectively. Methicillin-resistant
Staphylococcus aureus rates declined from 55% to 2.9%, whilst
extended spectrum ß-Lactamase-producing Klebsiella and E. coli
increased from 15.38% to 26.92% and 0% to 16.53%, respec-
tively. The use of guidelines, restrictive antibiotic policies, and
antibiograms has improved the empiric use of antibiotics.
Most microbiology products were available in 2015, enhanced
by a local emergency procurement fund. The hospital
Infection Prevention and Control Committee meets regularly,
develops policies, guidelines, and procedures as well as over-
sees implementation. The results of a survey and action plan
to improve hand hygiene were also discussed.
Brighid Malone and Gobuiwang Kurusa (Bokamoso Private
Hospital, Botswana) discussed ongoing activities in Bokamoso
Hospital to improve antibiotic utilization. These include the
development of an Infection Control Committee, biannual
antibiograms focusing more recently on ESKAPE organisms,
an active multidisciplinary DTC with the ASP as a subcommit-
tee meeting once-monthly, as well as the development of
treatment guidelines based on the Botswana Antibiotic
Guidelines, the WHO, the South Africa ASP, and other guide-
lines where necessary. The function of antibiograms is to
guide empiric use as well as monitor the emergence of resis-
tant strains. They also help gain closer collaboration between
clinicians and microbiology staff, especially for managing dif-
ficult and unusual infections. The ASP in Bokamoso is led by
an Infectious Disease (ID) Specialist and a Clinical Pharmacist,
with close collaboration between ID specialist/pharmacists
with Infection Control as well as with the Hospital administra-
tion under quality assurance and patient safety. As part of the
program, antimicrobial use can be measured and tracked, with
the potential for prospective interventions and feedback.
Areas of focus include dose optimization, parenteral to oral
switch, as well as time to first antibiotic dose.
Thatayaone Didimalang (Gaborone Private Hospital,
Botswana) discussed current ASPs at Gaborone Private
Hospital. The ASP consists of a multidisciplinary team with
active participation involving all key stakeholder groups.
Materials and guidance, including issues such as the duration
of therapy, are prominently displayed. Roles and responsibil-
ities are clearly defined for hospital managers, nursing staff,
infection prevention specialists, unit managers, pharmacists,
and physicians. Implementation is centered on four pillars:
Phase 1—establishing a framework, Phase 2—pharmacy and
nursing, Phase 3—progress evaluation, and Phase 4—clinical
guidelines. There are ongoing audits and feedback to improve
the use of antibiotics and this will continue. Mosana Moyo
(Gaborone Private Hospital, Botswana) subsequently discussed
current antibiotic sensitivities, which feed into any ASP.
Summary of gram-negative bacteria revealed the following:
(i) amoxacillin and cotrimoxazole cannot be used as first-line
therapy; (ii) cephalosporins exhibited a high degree of sensi-
tivity although the first generation should only be used to
treat cystitis; (iii) fluoroquinolones demonstrated high levels of
resistance; and (iv) carbapenems and aminoglycosides showed
good sensitivity. No vancomycin-resistant Enterococci were
found and only 11% Staphylococcus aureus isolates showed
methicillin resistance.
The remainder of the meeting was devoted to developing a
draft protocol with a PPS design in both private and hospital
sectors in Botswana and possibly widening the scope into
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Tanzania and Zimbabwe. The draft data-collection form had a
set of instructions and thereafter was divided into several parts.
Part one includes basic data on the hospital or study setting
(completed only once) with part two including data relating to
the ward, specialty, and census. Part three includes patient
demographic information, diagnosis, risk factors, antibiotic his-
tory, a review of current antibiotic prescriptions, and WHO core
drug-use indicators. Part four includes data to assess current
microbiology services and capacity, the functioning of DTCs,
Infection Prevention and Control committees, ASPs, and guide-
line dissemination. The variables were mostly aligned to that of
the European Centre for Disease Prevention and Control PPS
study [23] to enable comparisons to be drawn.
The next steps include refining the protocol, seeking ethical
approval, piloting the study, and subsequently undertaking
the study among hospitals in Botswana. The intention is to
present the findings at the next MURIA meeting in Botswana
in July 2016 as a basis for developing future pertinent inter-
ventions. Consequently, further enhance the appropriate use
of antibiotics in Botswana and further afield in Africa.
Conclusion
The 2-day meeting drew together key personnel and expertise
from the WHO and Botswana, as well as representatives from
Tanzania and Zimbabwe, to debate and plan research activ-
ities in Africa to help enhance the rational use of antibiotics.
The first step in the process is to gain a better understanding
of current antibiotic utilization patterns alongside resistance
patterns. This is now ongoing.
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